---
created: 2025-04-13
updated: 2025-04-13T10:52
id: Q&P09We)Y2
specialty: cardio
specialty_id: 218
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::07-cardiovascular::05-pharm::03-calcium-channel-blockers
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::09-cardiac
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::10-cardiac::01-hypertension-treatment
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::10-cardiac::02-calcium-channel-blockers
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::02-cardio-&-renal::03-antihypertensives::01-calcium-channel-blockers
  - source/ak-step1-v11::$ankingupdates::$errata::v11
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
  - source/ak-step1-v11::^systems::cardio::pharmacology
  - "source/ak-step2-v11:": 
  - theme/b&b::01-cardiology::pharm::cvs-pharm-1"
type: flashcard
---

# Question
**Verapamil::Drug** is a Ca2+ channel blocker that may cause hyper-**prolactinemia** as an adverse effect

---

# Answer
